This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Novartis Ag. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2023
Title: Brian Addison Dechristopher: Innovator in Metabolic Disorder Treatments
Introduction
Brian Addison Dechristopher is a notable inventor based in Belmont, MA (US). He has made significant contributions to the field of metabolic disorders through his innovative research and development of new compounds.
Latest Patents
Dechristopher holds 2 patents related to cyclic tetramer compounds that act as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These patents focus on the treatment of metabolic disorders, particularly in relation to cholesterol lipid metabolism. The disclosures detail the compounds' formulas and their potential applications in treating diseases influenced by PCSK9.
Career Highlights
Brian Dechristopher is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and contribute to advancements in medical treatments.
Collaborations
Throughout his career, Dechristopher has collaborated with notable colleagues, including Karin Briner and Alec Nathanson Flyer. These partnerships have enhanced his research efforts and broadened the impact of his inventions.
Conclusion
Brian Addison Dechristopher is a prominent inventor whose work in developing PCSK9 inhibitors is paving the way for new treatments in metabolic disorders. His contributions to the field are significant and continue to influence healthcare advancements.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile